Aug 2026 (Q2 FY27) — Oct 8, 2026
Park Aerospace Q2 FY27 — Sales at upper end of range, EBITDA beat, missile mix rising, Tulsa/ArianeGroup build-out
Read the full callPark Aerospace (PKE) earnings
- Aug 2026
- Aug 2026 (Q2 FY27)
- Mar 2026
Park Aerospace earnings: last reported Thu, 8 Oct 2026, for the quarter ended Aug 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 20.8 | +26.9% YoY | Quarterly, as filed | Quarter to Aug 2026 | Revenue from operations as filed. |
| Operating margin | 22.8 | +5.4 pts YoY | Operating profit / revenue | Quarter to Aug 2026 | For the quarter; a change is in percentage points. |
| Net profit | 4.5 | +88.6% YoY | Quarterly, as filed | Quarter to Aug 2026 | Profit after tax as filed. |
Price
$26.17 −0.53% · −$0.14
Performance +34.6% 1Y
1Y: $19.44 on 17 Oct 2025 → $26.17. High $38.23 (1 Jul 2026), low $18.55 (17 Nov 2025).
- Previous close
- $26.31
- 52-week range
- $18.55 – $38.23
- One year
- +30.33%
Overview
- Symbol
- PKE
- Sector
- Industrials
- Exchange
- US
- Currency
- USD
Call summaries
Jun 2026 (Q1 FY27) — Jul 20, 2026
Park Aerospace Q1 FY27 — Strong Margins, Missile Systems Expansion, and New Plant Development
Read the full callMar 2026 (Q4 FY26) — May 28, 2026
Park Aerospace Corp. Q4 FY26 — Commercial Aircraft & Missile Systems Juggernauts Drive Growth; Strategic Capital Actions
Read the full callEvery analysed call
Park Aerospace earnings calls (PKE)
Financials
What the filings say
Net profit, year on year: +89% (quarter to aug 2026 against aug 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Aug 2025 | Nov 2025 | Mar 2026 | May 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 17 | 15 | 16 | 17 | 24 | 18 | 21 |
| Operating profit | 2 | 3 | 2 | 3 | 4 | 5 | 4 | 5 |
| Operating margin | 12.8% | 16.8% | 15.7% | 17.4% | 21.0% | 19.0% | 21.9% | 22.8% |
| Profit before tax | 2 | 3 | 3 | 3 | 4 | 5 | — | 6 |
| Tax rate | 26.2% | 60.9% | 25.0% | 25.7% | 26.0% | 23.9% | — | 18.6% |
| Net profit | 2 | 1 | 2 | 2 | 3 | 4 | 4 | 5 |
| EPS ($ per share) | 0.08 | — | 0.10 | 0.12 | 0.15 | — | 0.17 | 0.21 |
| Line item | Mar 2019 | Mar 2020 | Feb 2021 | Feb 2022 | Feb 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | -3 | -22 | -25 | -25 | -43 | -45 | -50 | -48 |
| Total liabilities | 30 | 30 | 28 | 25 | 43 | 19 | 15 | 12 |
| Fixed assets | 11 | 16 | 21 | 24 | 24 | 23 | 22 | 22 |
| Investments | 81 | 117 | 75 | 98 | 101 | 71 | 47 | 11 |
| Total assets | 189 | 172 | 164 | 161 | 159 | 132 | 122 | 142 |
| Line item | Mar 2019 | Mar 2020 | Feb 2021 | Feb 2022 | Feb 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 8 | 5 | 13 | 8 | 6 | 4 | 5 | 11 |
| Cash from investing | 154 | -43 | 33 | -30 | -7 | 31 | 24 | 35 |
| Cash from financing | -106 | -28 | -10 | -7 | -8 | -33 | -14 | 11 |
| Net cash flow | 53 | -66 | 36 | -29 | -9 | 2 | 15 | 57 |
| Capital expenditure | -3 | -7 | -7 | -4 | -1 | -1 | -1 | -2 |
| Free cash flow | 5 | -2 | 6 | 4 | 5 | 4 | 4 | 9 |
Insider filings
29 filings between Oct 24, 2025 and Aug 13, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$9.50M
8 sales by 4 insiders
Compensation
not trading decisions- 21
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| SHORE BRIAN E | — | $5.89M | Aug 13, 2026 |
| Esquivel Mark A | — | $3.47M | Aug 13, 2026 |
| Petropoulos Constantine | — | $90.0K | Jul 27, 2026 |
| Smith Carl William | — | $58.3K | Nov 6, 2025 |
Latest filings (48)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | SHORE BRIAN E Board Chairman & CEO | Sale | 15,000 | $566.3K |
| Aug 13, 2026 | Esquivel Mark A President & COO | Option exercise | 5,000 | $64.0K |
| Aug 13, 2026 | Esquivel Mark A President & COO | Option exercise | 20,000 | $221.2K |
| Aug 13, 2026 | Esquivel Mark A President & COO | Sale | 40,000 | $1.48M |
| Aug 13, 2026 | Esquivel Mark A President & COO | Option exercise | 15,000 | $196.2K |
| Aug 13, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 7,500 | $99.5K |
| Aug 13, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 7,500 | $105.0K |
| Aug 12, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 18,750 | $245.3K |
| Aug 12, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 7,500 | $99.5K |
| Aug 12, 2026 | SHORE BRIAN E Board Chairman & CEO | Sale | 65,000 | $2.48M |
| Aug 12, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 8,750 | $112.0K |
| Aug 12, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 30,000 | $331.8K |
| Aug 11, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 25,000 | $289.5K |
| Aug 11, 2026 | SHORE BRIAN E Board Chairman & CEO | Sale | 46,250 | $1.73M |
| Aug 11, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 21,250 | $272.0K |
| Aug 10, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 25,000 | $361.0K |
| Aug 10, 2026 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 5,000 | $57.9K |
| Aug 10, 2026 | SHORE BRIAN E Board Chairman & CEO | Sale | 30,000 | $1.11M |
| Jul 29, 2026 | Esquivel Mark A President & COO | Option exercise | 15,000 | $216.6K |
| Jul 29, 2026 | Esquivel Mark A President & COO | Option exercise | 25,000 | $289.5K |
| Jul 29, 2026 | Esquivel Mark A President & COO | Option exercise | 20,000 | $256.0K |
| Jul 29, 2026 | Esquivel Mark A President & COO | Sale | 60,000 | $1.99M |
| Jul 27, 2026 | Petropoulos Constantine See Remarks | Option exercise | 2,500 | $35.0K |
| Jul 27, 2026 | Petropoulos Constantine See Remarks | Sale | 2,500 | $90.0K |
| Jun 9, 2026 | WARSHAW STEVEN T Director | Option exercise | 3,500 | $38.7K |
| Nov 12, 2025 | Nickel Cory Sr VP and General Manager | Option exercise | 250 | $1.3K |
| Nov 6, 2025 | Smith Carl William Director | Sale | 3,000 | $58.3K |
| Nov 4, 2025 | Smith Carl William Director | Option exercise | 3,000 | $15.7K |
| Oct 24, 2025 | WARSHAW STEVEN T Director | Option exercise | 3,000 | $15.7K |
| Jul 23, 2025 | Smith Carl William Director | Option exercise | 7,500 | $143.2K |
| Jul 14, 2025 | Smith Carl William Director | Option exercise | 7,500 | $65.3K |
| Apr 22, 2025 | Esquivel Mark A President & COO | Option exercise | 15,000 | $78.5K |
| Feb 11, 2025 | WARSHAW STEVEN T Director | Option exercise | 3,000 | $37.4K |
| Feb 6, 2025 | Blanchfield Dale Director | Option exercise | 3,000 | $37.4K |
| Feb 5, 2025 | SHORE BRIAN E Board Chairman & CEO | Option exercise | 35,000 | $183.1K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 35 | $525 |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 25 | $375 |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 975 | $14.6K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 500 | $7.5K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 200 | $3.0K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 100 | $1.5K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 932 | $14.0K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 68 | $1.0K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 365 | $5.5K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 200 | $3.0K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 100 | $1.5K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Sale | 1,000 | $15.0K |
| Jan 28, 2025 | Esquivel Mark A President & COO | Option exercise | 4,500 | $56.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PARK AEROSPACE CORP
Free account. Everything above stays public.
Write why you follow PARK AEROSPACE CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading